메뉴 건너뛰기




Volumn 69, Issue 4, 2010, Pages 391-400

Levofloxacin can be used effectively as a positive control in thorough QT/QTc studies in healthy volunteers

Author keywords

Clinical trial; Healthy subject; Levofloxacin; Moxifloxacin; QTc

Indexed keywords

IZILOX; LEVOFLOXACIN; MOXIFLOXACIN; PLACEBO; UNCLASSIFIED DRUG;

EID: 77949402826     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03595.x     Document Type: Article
Times cited : (31)

References (30)
  • 1
    • 27744587040 scopus 로고    scopus 로고
    • Clinical trial design to evaluate the effects of drugs on cardiac repolarization: Current state of the art
    • Camm AJ. Clinical trial design to evaluate the effects of drugs on cardiac repolarization: current state of the art. Heart Rhythm 2005; 2 (2 Suppl.): S23-9.
    • (2005) Heart Rhythm , vol.2 , Issue.2 SUPPL.
    • Camm, A.J.1
  • 2
    • 77949415660 scopus 로고    scopus 로고
    • ICH E14 The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs. International Conference on Harmonisation Step 4 Guideline, EMEA, CHMP/ICH/2/04. 25-5-2005.
    • ICH E14 The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs. International Conference on Harmonisation Step 4 Guideline, EMEA, CHMP/ICH/2/04. 25-5-2005.
  • 3
    • 0035293881 scopus 로고    scopus 로고
    • Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes
    • Owens RC Jr. Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes. Pharmacotherapy 2001; 21: 301-19.
    • (2001) Pharmacotherapy , vol.21 , pp. 301-319
    • Owens Jr., R.C.1
  • 5
    • 0034525584 scopus 로고    scopus 로고
    • Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects
    • Demolis JL, Kubitza D, Tenneze L, Funck-Brentano C. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clin Pharmacol Ther 2000; 68: 658-66.
    • (2000) Clin Pharmacol Ther , vol.68 , pp. 658-666
    • Demolis, J.L.1    Kubitza, D.2    Tenneze, L.3    Funck-Brentano, C.4
  • 6
    • 0035170062 scopus 로고    scopus 로고
    • Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG
    • Kang J, Wang L, Chen XL, Triggle DJ, Rampe D. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Mol Pharmacol 2001; 59: 122-6.
    • (2001) Mol Pharmacol , vol.59 , pp. 122-126
    • Kang, J.1    Wang, L.2    Chen, X.L.3    Triggle, D.J.4    Rampe, D.5
  • 7
    • 27744502903 scopus 로고    scopus 로고
    • The assessment of QT/QTc interval prolongation in clinical trials: A regulatory perspective
    • Strnadova C. The assessment of QT/QTc interval prolongation in clinical trials: a regulatory perspective. Drug Information J 2005; 39: 407-33.
    • (2005) Drug Information J , vol.39 , pp. 407-433
    • Strnadova, C.1
  • 8
    • 0842284660 scopus 로고    scopus 로고
    • A definitive or thorough phase 1 QT ECG trial as a requirement for drug safety assessment
    • Morganroth J. A definitive or thorough phase 1 QT ECG trial as a requirement for drug safety assessment. J Electrocardiol 2004; 37: 25-9.
    • (2004) J Electrocardiol , vol.37 , pp. 25-29
    • Morganroth, J.1
  • 9
    • 1942476132 scopus 로고    scopus 로고
    • Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings
    • Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J. Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings. J Clin Pharmacol 2004; 44: 464-73.
    • (2004) J Clin Pharmacol , vol.44 , pp. 464-473
    • Noel, G.J.1    Goodman, D.B.2    Chien, S.3    Solanki, B.4    Padmanabhan, M.5    Natarajan, J.6
  • 12
    • 33644861943 scopus 로고    scopus 로고
    • Effect of ciprofloxacin and levofloxacin on the QT interval: Is this a significant 'clinical' event?
    • Makaryus AN, Byrns K, Makaryus MN, Natarajan U, Singer C, Goldner B. Effect of ciprofloxacin and levofloxacin on the QT interval: is this a significant 'clinical' event? South Med J 2006; 99: 52-6.
    • (2006) South Med J , vol.99 , pp. 52-56
    • Makaryus, A.N.1    Byrns, K.2    Makaryus, M.N.3    Natarajan, U.4    Singer, C.5    Goldner, B.6
  • 13
    • 27744502903 scopus 로고    scopus 로고
    • The assessment of QT/QTc interval prolongation in clinical trials: A regulatory perspective
    • Strnadova C. The assessment of QT/QTc interval prolongation in clinical trials: a regulatory perspective. Drug Information J 2005; 39: 407-33.
    • (2005) Drug Information J , vol.39 , pp. 407-433
    • Strnadova, C.1
  • 14
    • 11144273910 scopus 로고    scopus 로고
    • Sample size, power calculations, and their implications for the cost of thorough studies of drug induced QT interval prolongation
    • Malik M, Hnatkova K, Batchvarov V, Gang Y, Smetana P, Camm AJ. Sample size, power calculations, and their implications for the cost of thorough studies of drug induced QT interval prolongation. Pacing Clin Electrophysiol 2004; 27: 1659-69.
    • (2004) Pacing Clin Electrophysiol , vol.27 , pp. 1659-1669
    • Malik, M.1    Hnatkova, K.2    Batchvarov, V.3    Gang, Y.4    Smetana, P.5    Camm, A.J.6
  • 15
    • 0031903272 scopus 로고    scopus 로고
    • Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects
    • Stass H, Dalhoff A, Kubitza D, Schühly U. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother 1998; 42: 2060-5.
    • (1998) Antimicrob Agents Chemother , vol.42 , pp. 2060-2065
    • Stass, H.1    Dalhoff, A.2    Kubitza, D.3    Schühly, U.4
  • 16
    • 0032898860 scopus 로고    scopus 로고
    • Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man
    • Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999; 43 (Suppl. B): 83-90.
    • (1999) J Antimicrob Chemother , vol.43 , Issue.SUPPL. B , pp. 83-90
    • Stass, H.1    Kubitza, D.2
  • 17
    • 0035054726 scopus 로고    scopus 로고
    • Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials
    • Aminimanizani A, Beringer P, Jelliffe R. Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. Clin Pharmacokinet 2001; 40: 169-87.
    • (2001) Clin Pharmacokinet , vol.40 , pp. 169-187
    • Aminimanizani, A.1    Beringer, P.2    Jelliffe, R.3
  • 19
    • 0030790098 scopus 로고    scopus 로고
    • Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects
    • Chien SC, Chow AT, Natarajan J, Williams RR, Wong FA, Rogge MC, Nayak RK. Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects. Antimicrob Agents Chemother 1997; 41: 1562-5.
    • (1997) Antimicrob Agents Chemother , vol.41 , pp. 1562-1565
    • Chien, S.C.1    Chow, A.T.2    Natarajan, J.3    Williams, R.R.4    Wong, F.A.5    Rogge, M.C.6    Nayak, R.K.7
  • 20
    • 0033802359 scopus 로고    scopus 로고
    • Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers
    • Lubasch A, Keller I, Borner K, Koeppe P, Lode H. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 2000; 44: 2600-3.
    • (2000) Antimicrob Agents Chemother , vol.44 , pp. 2600-2603
    • Lubasch, A.1    Keller, I.2    Borner, K.3    Koeppe, P.4    Lode, H.5
  • 21
    • 77949390566 scopus 로고    scopus 로고
    • ICH E14 The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs. International Conference on Harmonisation. E14 Implementation and Working Group, Questions and Answers. 4-6-2008.
    • ICH E14 The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs. International Conference on Harmonisation. E14 Implementation and Working Group, Questions and Answers. 4-6-2008.
  • 23
    • 35248869253 scopus 로고    scopus 로고
    • Levocetirizine does not prolong the QT/QTc interval in healthy subjects: Results from a thorough QT study
    • Hulhoven R, Rosillon D, Letiexhe M, Meeus MA, Daoust A, Stockis A. Levocetirizine does not prolong the QT/QTc interval in healthy subjects: results from a thorough QT study. Eur J Clin Pharmacol 2007; 63: 1011-7.
    • (2007) Eur J Clin Pharmacol , vol.63 , pp. 1011-1017
    • Hulhoven, R.1    Rosillon, D.2    Letiexhe, M.3    Meeus, M.A.4    Daoust, A.5    Stockis, A.6
  • 28
    • 41549161099 scopus 로고    scopus 로고
    • Effect of levetiracetam on cardiac repolarization in healthy subjects: A single-dose, randomized, placebo- and active-controlled, four-way crossover study
    • Hulhoven R, Rosillon D, Bridson WE, Meeus MA, Salas E, Stockis A. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study. Clin Ther 2008; 30: 260-70.
    • (2008) Clin Ther , vol.30 , pp. 260-270
    • Hulhoven, R.1    Rosillon, D.2    Bridson, W.E.3    Meeus, M.A.4    Salas, E.5    Stockis, A.6
  • 29
    • 37549043173 scopus 로고    scopus 로고
    • Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: A possible role as CYP3A inhibitor in thorough QTc studies
    • Epub Jun 20
    • Sarapa N, Nickens DJ, Raber SR, Reynolds RR, Amantea MA. Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies. Clin Pharmacol Ther 2008; 83: 153-9. Epub 2007 Jun 20.
    • (2007) Clin Pharmacol Ther 2008 , vol.83 , pp. 153-159
    • Sarapa, N.1    Nickens, D.J.2    Raber, S.R.3    Reynolds, R.R.4    Amantea, M.A.5
  • 30
    • 1942476132 scopus 로고    scopus 로고
    • Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings
    • Noel GJ, Goodman DB, Chien S, Solanki B, Padmanabhan M, Natarajan J. Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings. J Clin Pharmacol 2004; 44: 464-73.
    • (2004) J Clin Pharmacol , vol.44 , pp. 464-473
    • Noel, G.J.1    Goodman, D.B.2    Chien, S.3    Solanki, B.4    Padmanabhan, M.5    Natarajan, J.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.